WO2003094927A1 - Method of inhibiting d-glucose absorption and d-glucose absorption inhibitor - Google Patents

Method of inhibiting d-glucose absorption and d-glucose absorption inhibitor Download PDF

Info

Publication number
WO2003094927A1
WO2003094927A1 PCT/JP2003/005661 JP0305661W WO03094927A1 WO 2003094927 A1 WO2003094927 A1 WO 2003094927A1 JP 0305661 W JP0305661 W JP 0305661W WO 03094927 A1 WO03094927 A1 WO 03094927A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucose
arabinosu
food
absorbed
absorption
Prior art date
Application number
PCT/JP2003/005661
Other languages
French (fr)
Japanese (ja)
Inventor
Yoshihiro Nishikawa
Hideki Yamamoto
Soichi Arai
Original Assignee
Unitika Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002-131552 priority Critical
Priority to JP2002131552A priority patent/JP2003319758A/en
Application filed by Unitika Ltd. filed Critical Unitika Ltd.
Publication of WO2003094927A1 publication Critical patent/WO2003094927A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/163Sugars; Polysaccharides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Abstract

It is intended to provide a novel method or foods and drinks for inhibiting the absorption of D-glucose which show an excellent dieting effect and an effect of controlling blood glucose level on persons with excessive calorie intake, persons with obesity or diabetics. Namely, a method of inhibiting the absorption of D-glucose characterized by comprising, at the intake of D-glucose or a carbohydrate containing D-glucose as one of its constituting sugars, taking L-arabinose or an L-arabinose-containing material simultaneously with the intake and/or before or after the intake.

Description

Specification

D one Darukosu resorptive process and D- Darukosu absorption inhibitor <art>

The present invention, various food products glycemic 'index method to De as possible D- glucose absorption inhibiting reducing the (GI value, blood sugar value increased area under the curve when taken various bran protein, corresponding to the total absorption) and to a food or beverage 及 Pipe Ttofudo with D- glucose absorption inhibitor, as well as the effect. Ingredients BACKGROUND>

D- glucose through the digestive tract is a substance of energy-saving one source via the glycolysis system and is absorbed into the body is a component indispensable when performing life activities. However, in recent years, D- glucose and carbohydrate to one constituting sugar D- glucose, specifically starch, adverse effects on health are obese due to excessive intake of such sucrose has become conspicuous. Obesity, hypertension, glucose intolerance, easily merged hyperlipidemia etc., ischemic heart disease, stroke, and also considered a risk factor for diabetes and the like, from the viewpoint of preventing geriatric diseases, the absorption of D- glucose combat obesity by inhibiting is extremely important.

So far, various components having anti-obesity effects have been reported, many of which are components with non one Darukoshidaze inhibitory activity. These were those with the effect of preventing obesity by two by inhibiting sugars and polysaccharide digestion suppressing the generation of free monosaccharides (mainly D- glucose), to reduce the absorption. L Arabinosu as one with such α one Darukoshidaze inhibitory activity have been known.

L Arabinosu has a taste similar to sucrose, a sugar of non-force opening Lee showing a poorly absorbed. In nature, it is present in the hemicellulose Arabinan, as a constituent sugar and the like of Arabinokishiran such as polysaccharides to the higher plants. In the single-sugar state, it is a fine amounts have been included in fermented foods such as miso and sake, to instant coffee and the like. L For the mechanism of action of the α- Darukoshidaze inhibition Arabinosu, Hinokisaku Susumu of published reports (J. A p 1. G lucosci., V ol. 46, NO. 2, p. 1

59 - are described in detail in 16 5 (1 99 9)). According to this, L Arabino scan duodenum, sucrase localized to the microvilli membrane surface of the small intestinal mucosa (mucosal brush border) a (disaccharide hydrolase) inhibit at non antagonistic (see FIG. 1). As a result, the decomposition of the ingested carbohydrate D- glucose or D- fructose is as occurs slowly, the less absorption in the duodenum and jejunum upper small intestine middle, so to digest absorb at the bottom. That is, since using the entire intestinal absorption of monosaccharides is conducted Gently steep increase in blood glucose level after meals suppressed (Kachinuka), satiety persists, since it is suppressed appetite, Daietsuto effect it is that the show.

Also, the selectivity of the flight one Darukoshidaze inhibition of L- Arabinosu, S eri et al published reports (Me tabolism, Vo l. 45, No. 1 1, p. 1 36 8- 1 374 (1 996)) to the It is described in detail. According to this, L Arabino scan is selectively inhibited Shiyutaraze, maltase, Ratataze like, other alpha - has become inhibition is not substantially observed for the Dal Koshidaze. Furthermore, D- although also mention absorption inhibiting action of the Dal course, in mice loaded with D- Darko one scan of 1 gZKg, 2. 5~ 1 0 wt% coexist L Arabinosu against D- glucose the effect of suppressing the absorption of is not even D- glucose was that not a recognized. That is, until the L Arabinosu This, because hardly inhibit sucrase except disaccharide hydrolytic hydrolase is a disaccharide hydrolyzates enzyme in sucrose, but to suppress an increase in blood glucose level caused by the ingestion of sucrose, D- glucose itself it was not known to suppress an increase in blood glucose level caused by the ingestion of ingestion Ya sucrose than sugar sugars.

On the other hand, as a substance that suppresses the absorption of D- glucose directly, gymnemic acid, but full opening lysine and the like are known, which are used to affect the taste of the food, some processing in the case of adding to the food there is a need to perform. Phlorizin medical, are used for research, is expensive to use in food, also there was a problem in safety when ingested in large amounts. The present invention has no problem in the safety in use in foods, beverages, and low cost, and its object is to provide methods and inhibiting the absorption of D- glucose. Disclosure of Ku invention>

The present inventors have made intensive studies to solve the above problem, until now, the effect of suppressing the rise in blood glucose level during disaccharide intake by suppressing digestion disaccharide, i.e., ct one Darukoshidaze inhibition for a to known was L- Arabinosu with activity, when allowed to coexist amount above a certain concentration with respect to D- glucose, new finding that D- Darco one scan absorption itself is suppressed (FIG. 2 to obtain a reference), it has completed the present invention. Specifically, a first aspect of the present invention are those of glucose D- is when it is absorbed into the living cells, and gist characterized to D- Darukosu resorptive how to that coexist L _ Arabinosu, preferably, biological cells are intestinal inner wall epithelial cells. As the preferred means coexist L Arabinosu, D- glucose or the time of ingested carbohydrate that is digested to comprise D- glucose as one of the constituent sugars D- Darukosu intake simultaneously and or longitudinal to those to feed the L Arabinosu or L Arabinosu inclusions.

Second aspect of the present invention, D is characterized by an active ingredient L Arabinosu - it is an gist Darukosu absorption inhibitor.

A third aspect of the present invention is absorbed in the food or drink containing sugar, among D- glucose contained as D _ Darco one scan and configuration sugars in and drink food, the living body when the L- Arabinosu does not coexist relative to the amount that is, it is an gist food or beverage which is characterized in that it contains the amount of L- Arabino over scan more than 1 0% by weight.

A fourth aspect of the present invention is a pet food containing carbohydrate, among D- glucose contained as D- glucose and constituent sugars in the pet food is absorbed in the living body when the L- Arabino over scan does not coexist that with respect to the amount, 1 is 0 also to the gist Bae Ttofu one de, characterized in that mass% more than the amount of L Arabinosu are included. <BRIEF DESCRIPTION OF THE DRAWINGS>

Figure 1 is a schematic diagram showing an operation of L Arabinosu previously known.

Figure 2 is a schematic diagram showing an operation of this newly found L- Arabinosu. Figure 3 is a graph showing the results of a blood glucose increase inhibition test according D- glucose tolerance. Figure 4 is a graph showing the results of a blood glucose increase inhibition test by maltose load. Figure 5 is a graph showing the results of a blood glucose increase inhibition test by trehalose load. BEST MODE FOR CARRYING OUT THE ku invention>

The present invention will be described in detail.

In the present specification, "mass%" is synonymous with "weight%". Hereinafter sometimes abbreviated as "%".

L Arabinosu used in the present invention include powders, molasses, crystal or granule or the like, all forms that can be used. Further, Arabinan, Arabinokishiran or natural products containing § Rabbi Bruno Galata Tan, Arabinan, Arabinokishiran or § rabbi Roh enzyme treated natural products obtained by enzymatic treatment directly by junk emissions enzyme L- § arabinose is liberated and. it may be extracts thereof.

Enzyme treatment natural product L Arabinosu is liberated and details of how to manufacture the extract method parallel Pini L over § arabinose-containing enzyme-treated product of L Arabinosu the present inventors previously developed and a method for producing (Japanese Patent Application No. 2 0 0 0 2 2 4 0 1 3, No. 2 0 0 0 2 8 8 7 4 5) which is incorporated herein by reference.

The method of D- glucose absorption inhibiting first aspect of the present invention, the above-mentioned L Arabinosu, in which coexist in glucose D- is absorbed in the living cell. The biological, mammals, birds, reptiles, amphibians, etc. fish and the like. Is a mammal, primate of human, monkey, such as chimpanzees, I j, cat, Araidama, carnivores, such as Hue toilet, Usagi eyes, rats, hamsters, Monoremotto, rodents such as squirrels, koalas, kangaroos, etc. marsupial eye, © Perissodactyla such as, for example, between, and the like. These biological absorption of D- glucose is mainly performed by the intestinal inner wall epithelial cells. The amount of co is causing L Arabinosu and to absorbed D- glucose, 1 0-3 0% by weight (1 not including 0%), or, more, is preferred.

One Glucose is not limited to any method if coexisting L Arabinosu when absorbed, preferably constituting sugar D one glucose or D- glucose - method of D- glucose absorption inhibiting the invention, D Les, yo if caused to ingest L Ara Binosu or L- Arabinosu inclusions when to feed a carbohydrate that is digested comprising D- glucose or intake simultaneously and / or back and forth with.

Generally, D- glucose, is in the food present in the following forms.

1. Liberated state, i.e., it exists as a monosaccharide D- glucose,

2. Bound states, i.e., polysaccharides, it exists as a component of oligosaccharides D- glucose. 2. Of D- glucose is further classified into two.

(1) decomposed into the digested D- glucose absorbed D- glucose.

(2) decomposition undigested, unabsorbed D- glucose (such as dietary fibers such as cellulose).

As saccharide containing as one of the above 2. (1) of D- glucose constituent sugar, tio sugar, Ratatosu, Manoretosu, Isomarutosu, trehalose, Bruno Rachinosu, Chichihate oligosaccharide, flutter Toorigo sugar, Garatatoorigo sugar, isomalto-oligosaccharides, Ma Rutoorigo sugars, soybean oligosaccharides, raffinose, Genjiorigo sugar, Shikurodekisu preparative phosphorus, amylose, Amiro pectin, but the starch and the like, among these, the ones other than sucrose, not L Arabinosu inhibits the disaccharide hydrolase and the like which are considered a carbohydrate which is decomposed to D- glucose. The subject to suppression by L over § arabinose in the present invention is the 1. And 2. D one glucose corresponding to (1). Therefore in the present invention is to achieve the effect of suppressing even elevated blood glucose level caused by the ingestion of carbohydrates other than sucrose.

L When ingesting Arabinosu or L- Arabinosu inclusions, D- Darko includes over scan or D- glucose as a constituent sugar when to feed a carbohydrate that is digested to D- glucose, at the same time or before and after it is, but before and after the time, depending on the intake of L Arabinosu or L Arabinosu inclusions, D- when the dull course is absorbed, as L Arabinosu, 1 0 3 0 mass 0/0 (1 exclusive of 0%), or not particularly limited as long as more even so as to extent coexist. Good Mashiku is, D- glucose or D- glucose containing as one of the constituent saccharides D- glucose until the the before taking 1 2 0 min after carbohydrate digestion, Ru 1 2 0 minutes prior der after ingestion. And still more preferably ingested before 6 0 minutes later.

Incidentally, it is Rukoto give effects of the present invention have taken from the corresponding previously when the L Arabinosu or L Arabinosu inclusions can be controlled to elution time such as capsules.

The amount intake L- Arabinosu or L- Arabinosu inclusions, glucose D- exceeds when absorbed in the intestine, the 1 0% by weight relative to D one glucose absorbed when L Arabinosu is absent not particularly limited, so accustomed to as L Arabinosu coexist. Exist in a state of D- glucose contained in food products to be ingested, when present in the form (monosaccharide) you release Yu and bound state, ie a polysaccharide, be it the oligosaccharide components is digested to case, it is necessary to ingest the amount of L- Arapino over scan more than 1 0% by weight with respect to the D- glucose contained in foods to be ingested.

Meanwhile, the D- glucose contained in food products to be ingested, bound state, Sunawa Chi polysaccharides, if also be present as a component of oligosaccharides include D- glucose undigested is contained in the food it may be ingested amount of L Arabino scan more than 1 0% by weight, based on the amount that subtracted D- glucose levels that are not digested by the total D- amount of glucose. For example, among the total D- glucose contained in food products to be ingested, if D- glucose 50% is not digested, the amount of more than 5 wt% with respect to which Ru D- glucose contained in foods to be ingested it is sufficient intake of Roh L- Arabinosu.

Therefore, the intake of specific L Arabinosu when to eat, the L Arabinosu dependent on D- glucose levels and D- Dal course amount of digestion and absorption of the monosaccharides contained in the foods you intake there is a need to be taken. Those human 及 Pi animals ingest as Sakae Yogen can be roughly categorized into carbohydrates, proteins, can min Keru be fat. Individual difference is large in the human, generally to the Japanese, the proportion of carbohydrates (sugar) is, 6 5. 7% (F AO "Sixth World Food Survey" 1 979- 1 98 1-year average) and large (fat: 22.3%), large and the proportion is 38.8% occupied by the fat (FAO "sixth world food survey" 1 979 _ 1 98 1-year average) in the United States (carbohydrate: 49.1% ). Age of the Japanese, in the gender average, intake of carbohydrates of the day 1 80, which is 323 g from g (2000 year National Nutrition tone 查 Ministry of Health, Labor and Welfare Department of Health Affairs Division lifestyle-related disease measures room Nutrition Survey engagement). Although D- glucose amount of this out undigested is not clear to what extent, for the nutritional requirements of the Sixth revised Japanese intake of (Ministry of Health Health stations lifestyle-related disease measures room), the dietary fiber is 20 from it is desirable that the 25 g / day, has become.

From the above article, when exist as a free state (monosaccharides) and components of the polysaccharides to estimate daily intake of D- glucose digested, in the case of Japanese, 1 50 from 300 g extent, in the case of Amerika person, assuming 75% of the Japanese (the ratio of carbohydrate), consisting of 1 1 0. 225 g.

Individual differences, there is a daily rate, the dosage of L Arabinosu, in a single meal, 3. 5 g or more, preferably 5 g or more, more preferably 10 g or more. It is not necessary to ingest always L Arabinosu in diet all the daily intake over LLG, preferably, 1 5 g or more, further preferably 30 g or more. In addition, without regard to the meal, snack according to the (snack, intake of drinks, etc.), it is also possible to ingest only in order to reduce the influence of the intake D- glucose. D- glucose absorption inhibitor of the second aspect of the present invention has as an active Ingredient The L Arabinosu was the L- Arabinosu is used. The form of the L Arabino scan, powder, molasses, crystal or granule or the like, L- Arabinosu intact enzyme treated natural products Contact Yopi the extract liberated, or water, ethanol, E Chirenguriko ^, such as polyethylene glycol liquid carriers, cellulose, and diluted with non-toxic carriers such as solid carriers, such as Poria Mi de powder, ampoules, granules, tablets, pills, capsules, include those prepared by a conventional method to syrups It is. The D- glucose absorption inhibitor of the present invention, included in the diet, (not including 1 0%) 1 0 to 30 wt% with respect to D- glucose is absorbed into the living body when the L Arabinosu does not coexist, or it may be for clothes to allow ingestion more L Arabinosu.

Food and drink of the third aspect of the present invention is, cookies, confectionery such as biscuits, Aisutari over-time, frozen desserts such as sherbet, coffee, other drinks, such as juice, sand sugar, bean paste, jam, such as cornflakes sugar than in food and drink, including the quality, of the D- glucose contained as is D- glucose and constituent sugars contained in the food or drink, a 1 0% by weight, based on the amount that is absorbed into a living body when L Ara Binosu does not coexist those containing an amount of L Arabinosu. Preferably, Ru 1 5 to 3 0% by weight Dea.

How to make the food and drink is not particularly limited, and may be added in the manufacturing process L- Arabinosu.

Pet food fourth aspect of the present invention are corn, wheat, rice, Enpaku acids, potatoes, beans, in pet food containing carbohydrates, such as fruits, as containing Murrell D- glucose and component sugars pet food of D- glucose contained, those containing an amount of L- Arabinosu that relative to the amount absorbed in the living body when the L- Arabinosu does not coexist exceeds the 1◦ mass%. Preferably, a 1 5 to 3 0% by weight.

How to make the pair Ttofu one de is not particularly limited, it may be added to L Arabino over scan in the manufacturing process.

<Example>

It will be specifically described by the present invention through examples. Example 1 (D-glucose load blood glucose increase inhibition test by)

Sample 1 shown in Table 1, 2 were prepared. W ISTAR rats (male, 1 group = 5 mice, 5 weeks old) were fasted from the day before the test, each of the samples 2 m L / l 0 0 g body weight (1 g / K g body weight equivalent) intragastric directly administered, predose and 1 5 minutes after the administration, 3 0 minutes, 6 0 minutes, 1 2 blood glucose monitoring instrument changes in blood glucose level of the tail venous blood at 0 minutes: Atora be sampled (Publisher: Teijin) in was measured. Numbers represent the amount of change in the blood sugar level before administration in blood sugar level, and the average mechanic standard deviation for each group (n = 5). table 1

Figure 3 shows the results. Although fluctuations in blood glucose sample 1 is going to sharply projecting Azukanochi 1 within 5 minutes (control), sample 2 (L-Arabinosu 2 0 Mass. / 0 added), the rise area itself of the blood glucose level since it is reduced to about 6 0%, c example 2 suggest that L _ Arabinosu is suppressed absorption itself D- glucose (blood glucose increase inhibition test according maltose load)

Except for using the samples shown in Table 2 was made in the same manner as in Example 1. Table 2

Figure 4 shows the results of a blood glucose increase inhibition test of Example 2. Although fluctuations in blood glucose level is going rapidly within 6 0 minutes after the administration in the sample 3 (control), sample 4 (L Arabinosu 2 0 wt% added), the increase in the area itself of the blood glucose level of about 6 0% since it is reduced to, the L- Arabinosu is suppressed absorption itself D-glucose is a decomposition product of maltose is suggested.

Example 3 (blood glucose increase inhibition test by trehalose load)

Except for using the samples shown in Table 3 were conducted as in Example 1. Table 3

Figure 5 shows the results of a blood glucose increase inhibition test of Example 3. Although fluctuations in blood glucose sample 5 has occurred rapidly within 6 0 minutes after the administration with (control), in the sample 6 (L Arabinosu 2 added 0 wt%), increase the area itself of the blood sugar level of about 70% since it is reduced to, L- Arabinosu is D is a decomposition product of trehalose - that suppresses the absorption itself glucose is suggested.

The present invention has been described with reference to also specific embodiments in detail, it is possible to make various changes and modifications without departing from the spirit and scope of the present invention is a connexion apparent to those skilled in the art.

The present application is based on Japanese Patent Application filed May 7, 2002 (Japanese Patent Application No. 2002- 131552), the contents of which are incorporated herein by reference. Ku Industrial Applicability>

Ingestion of D- glucose absorption inhibitor or the food of the present invention, D- glucose uptake excessive can be suppressed in, D- and gradual rise in blood glucose level caused by the ingestion of such glucose, thus the occurrence of obesity reduction, Obesity accompanied effect of preventing various diseases can be expected. In recent years, it is effective to reduce Dali cell Mick index values ​​of various foods has been attracting attention as obesity countermeasure (GI value).

Claims

The scope of the claims
1. D-when glucose is absorbed in the living cell, D- glucose absorption inhibiting method characterized by the coexistence of L Arabinosu.
2. Biological cells, D- glucose absorption inhibition method ranging first claim of claim is intestinal inner wall epithelial cells.
3. D- glucose or when to feed a carbohydrate that is digested to comprise D- glucose D- glucose as a constituent sugar, to feed the L Arabinosu or L Arabinosu inclusions after ingestion simultaneously and z or before the first term or method of D- glucose absorption inhibiting second claims claims, characterized in that.
4. Respect absorbed D- glucose in a biological, the claims that to feed to coexist L- Arabinosu 1 0-3 0% by weight (1 not including 0 mass%) and Features Darukosu resorptive process - D of the third term describes.
5. L-D-glucose absorption inhibitor, which comprises as an active ingredient Arabinosu.
6. In food or drink containing carbohydrate, relative to the amount absorbed in the living body of D- glucose contained as D- glucose and constituent sugars in and drink food, 1 0 wt. / More than 0 amount of food or drink, characterized in that L Arabinosu contains.
7. In pet food containing carbohydrate, relative to the amount absorbed in the living body of D- glucose contained as D- glucose and structure Naruto in The feed, in an amount exceeding 1 0 mass% L Arabinosu Bae Ttofu one de, characterized in that it contains.
PCT/JP2003/005661 2002-05-07 2003-05-06 Method of inhibiting d-glucose absorption and d-glucose absorption inhibitor WO2003094927A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2002-131552 2002-05-07
JP2002131552A JP2003319758A (en) 2002-05-07 2002-05-07 Method and inhibitor for inhibiting d-glucose absorption

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003231420A AU2003231420A1 (en) 2002-05-07 2003-05-06 Method of inhibiting d-glucose absorption and d-glucose absorption inhibitor

Publications (1)

Publication Number Publication Date
WO2003094927A1 true WO2003094927A1 (en) 2003-11-20

Family

ID=29416612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/005661 WO2003094927A1 (en) 2002-05-07 2003-05-06 Method of inhibiting d-glucose absorption and d-glucose absorption inhibitor

Country Status (3)

Country Link
JP (1) JP2003319758A (en)
AU (1) AU2003231420A1 (en)
WO (1) WO2003094927A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9483619B2 (en) 2012-09-11 2016-11-01 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120093975A1 (en) * 2009-05-14 2012-04-19 Pharmachem Laboratories, Inc. L-arabinose plus chromium for controlling the metabolization of sucrose

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0560284A1 (en) * 1992-03-10 1993-09-15 Godo Shusei Co., Ltd. Prophylactic and remedial preparation for diseases attendant on hyperglycemia, and wholesome food
WO1994012057A1 (en) * 1992-11-25 1994-06-09 Fujisawa Pharmaceutical Co., Ltd. Diet sweetener

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0560284A1 (en) * 1992-03-10 1993-09-15 Godo Shusei Co., Ltd. Prophylactic and remedial preparation for diseases attendant on hyperglycemia, and wholesome food
WO1994012057A1 (en) * 1992-11-25 1994-06-09 Fujisawa Pharmaceutical Co., Ltd. Diet sweetener

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9773096B2 (en) 2012-09-11 2017-09-26 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9483619B2 (en) 2012-09-11 2016-11-01 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US10410740B2 (en) 2012-09-11 2019-09-10 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9811638B2 (en) 2012-09-11 2017-11-07 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US10102922B2 (en) 2012-09-11 2018-10-16 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9965596B2 (en) 2012-09-11 2018-05-08 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9710611B2 (en) 2014-01-31 2017-07-18 Aseko, Inc. Insulin management
US9604002B2 (en) 2014-01-31 2017-03-28 Aseko, Inc. Insulin management
US9892235B2 (en) 2014-01-31 2018-02-13 Aseko, Inc. Insulin management
US9504789B2 (en) 2014-01-31 2016-11-29 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9965595B2 (en) 2014-01-31 2018-05-08 Aseko, Inc. Insulin management
US10255992B2 (en) 2014-01-31 2019-04-09 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US10128002B2 (en) 2014-10-27 2018-11-13 Aseko, Inc. Subcutaneous outpatient management
US10403397B2 (en) 2014-10-27 2019-09-03 Aseko, Inc. Subcutaneous outpatient management
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
US10380328B2 (en) 2015-08-20 2019-08-13 Aseko, Inc. Diabetes management therapy advisor

Also Published As

Publication number Publication date
JP2003319758A (en) 2003-11-11
AU2003231420A1 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
Buhler et al. Nutrition of Salmonoid Fishes: IX. Carbohydrate Requirements of Chinook Salmon
Cummings Nutritional implications of dietary fiber
Anderson et al. Plant fiber. Carbohydrate and lipid metabolism
Slavin et al. Dietary fibre and satiety
Cummings et al. A new look at dietary carbohydrate: chemistry, physiology and health
Sharma et al. Resistant starch: physiological roles and food applications
Butt et al. Guar gum: a miracle therapy for hypercholesterolemia, hyperglycemia and obesity
Vinik et al. Dietary fiber in management of diabetes
Cummings et al. Gastrointestinal effects of food carbohydrate
Asp Classification and methodology of food carbohydrates as related to nutritional effects
Aller et al. Starches, sugars and obesity
US20050079244A1 (en) Foodstuff
US5468734A (en) Prophylactic and remedial preparation for diseases attendant on hyperglycemia, and wholesome food
US20040147457A1 (en) Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glycemic index
Würsch et al. The role of viscous soluble fiber in the metabolic control of diabetes: a review with special emphasis on cereals rich in β-glucan
EP1067843B1 (en) Composition for improving glucose and insulin metabolism in companion animals
Southgate Digestion and metabolism of sugars
Kritchevsky Dietary fiber
Shetty et al. Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats
Jenkins et al. Relationship between rate of digestion of foods and post-prandial glycaemia
Wolever et al. Effect of dietary fiber and foods on carbohydrate metabolism
AU2008256938B2 (en) Edible composition comprising a slowly digestible or digestion resistant oligosaccharide composition
KR20150015030A (en) Novel sweetener having sucrose-like taste, method for producing the same, and use of the same
Potter et al. Effect of test meals of varying dietary fiber content on plasma insulin and glucose response
Salas-Salvadó et al. Dietary fibre, nuts and cardiovascular diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase